Indevus news from FierceBiotech
NewsIndevus shares plunge on approval delay
Indevus is facing a major setback in its efforts to gain approval for Nebido. The drug treats male hypogonadism, a condition in which the testicles fail to produce enough testosterone. Indevus said Read more...
ALSO NOTED: Adolor shares rise on NDA news; Indevus plans Phase III; Exelixis earns milestone; and much more...
> Shares of Adolor surged on the news that the FDA's Gastrointestinal Drugs Advisory Committee will review the new drug application for the pain drug Read more...
| Press ReleasesPRESS RELEASE: Indevus Receives Non-Approvable Letter From FDA for VALSTAR Indevus Receives Non-Approvable Letter From FDA for VALSTAR VALSTAR-specific Issues Have Been Resolved; Remaining Issues Pertain to cGMP Compliance of Third-party Manufacturing Facility Company Read more... PRESS RELEASE: Indevus Pharmaceuticals Reports Positive Results of Phase II Octreotide Implant Trial Indevus Pharmaceuticals Reports Positive Results of Phase II Octreotide Implant Trial Company Plans to Initiate Phase III Program in First Half of 2008 LEXINGTON, Mass., Nov. 28 -- Indevus Read more... PRESS RELEASE: Indevus Receives Approvable Letter From FDA for Valstar for Bladder Cancer TherapyIndevus Receives Approvable Letter From FDA for Valstar for Bladder Cancer Therapy LEXINGTON, Mass., Aug. 17 -- Indevus Pharmaceuticals, Inc. today announced that it has received an approvable letter Read more... |
Get more Indevus coverage at:
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends